Marea Therapeutics Raises $190M in Funding to Advance Medical Development

Marea Therapeutics raises $190M in Series A and B Financings

Marea Therapeutics (Linkedin), a clinical-stage biotechnology company, recently secured $190M in combined Series A and B financings. They are dedicated to developing innovative medicines for adults with metabolic dysfunction and high risk for cardiovascular disease.

Funding Amount: $190 million

Industry: E-Learning Providers

Employee Count: 2-10

CEO: Lindsay Tjepkema (CEO Linkedin)

What Marea Therapeutics needs to buy: Marea Therapeutics is seeking partnerships with clinical research organizations, manufacturers, and regulatory consultants to support their Phase 2 development plan and future clinical trials. Companies specializing in clinical research services, manufacturing and supply chain solutions, and regulatory expertise are ideal partners for Marea Therapeutics' growth and success in the biotechnology industry.